Overexpression of miR-483-5p/3p cooperate to inhibit mouse liver fibrosis by suppressing the TGF-β stimulated HSCs in transgenic mice

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 6, 2014, Pages 966-974

  Li, Fuyuan ^a   Ma, Ning ^a,b   Zhao, Ruiqi ^a   Wu, Guodong ^a   Zhang, Yanfen ^a   Qiao, Yu ^a   Han, Dong ^a   Xu, Ya ^a   Xiang, Ying ^a,c   Yan, Bingzhu ^d   Jin, Jianfeng ^a   Lv, Guixiang ^a   Wang, Lei ^a   Xu, Changqing ^a   Gao, Xu ^a,b,e   Luo, Shanshun ^f  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Translational Medicine Center of Northern China   (China)

^c YANGTZE UNIVERSITY   (China)

^d THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^e Biopharmaceutical Institute   (China)

^f THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

HSCs; Liver fibrosis; MicroRNA; Transgenic mice

Indexed keywords

CARBON TETRACHLORIDE; GELATINASE A; MESSENGER RNA; MICRORNA; MIRN483 MICRORNA, MOUSE; PLATELET DERIVED GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOMA, HEPATOCELLULAR; CELL CULTURE; CHEMICALLY INDUCED; COCULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; HUMAN; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLISM; MOUSE; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL; TRANSGENIC MOUSE;

ANIMALS; CARBON TETRACHLORIDE; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; COCULTURE TECHNIQUES; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRORNAS; PLATELET-DERIVED GROWTH FACTOR; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA;

EID: 84904654212     PISSN: 15821838     EISSN: 15824934     Source Type: Journal    
DOI: 10.1111/jcmm.12293     Document Type: Article

References (40)

1. Kew MC, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis. 1984; 4: 136-46.
2. Mallat A, Lotersztajn S. Novel insights into liver fibrosis. Am J Physiol Cell Physiol. 2013; 305: C789-99.
3. Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001; 107: 823-6.
4. Kogure T, Costinean S, Yan I, et al. Hepatic miR-29ab1 expression modulates chronic hepatic injury. J Cell Mol Med. 2012; 16: 2647-54.
5. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013; 10: 542-52.
6. Hsu SH, Wang B, Kota J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012; 122: 2871-83.
7. Randall G, Panis M, Cooper JD, et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci USA. 2007; 104: 12884-9.
8. Roderburg C, Urban GW, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011; 53: 209-18.
9. Trebicka J, Anadol E, Elfimova N, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol. 2013; 58: 234-9.
10. Köberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013; 49: 3442-9.
11. Ma N, Wang X, Qiao Y, et al. Coexpression of an intronic microRNA and its host gene reveals a potential role for miR-483-5p as an IGF2 partner. Mol Cell Endocrinol. 2011; 333: 96-101.
12. Gao X, Qiao Y, Han D, et al. Enemy or partner: relationship between intronic micrornas and their host genes. IUBMB Life. 2012; 64: 835-40.
13. Yao X, Hu JF, Daniels M, et al. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest. 2003; 111: 265-73.
14. Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009; 23: 2152-65.
15. Soon PS, Tacon LJ, Gill AJ, et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res. 2009; 15: 7684-92.
16. Veronese A, Lupini L, Consiglio J, et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res. 2010; 70: 3140-9.
17. Ma N, Li F, Li D, et al. Igf2-derived intronic miR-483 promotes mouse hepatocellular carcinoma cell proliferation. Mol Cell Biochem. 2012; 361: 337-43.
18. Maubach G, Lim MC, Chen J, et al. miRNA studies in in vitro and in vivo activated hepatic stellate cells. World J Gastroenterol. 2011; 17: 2748-73.
19. Veronese A, Visone R, Consiglio J, et al. Mutated beta-catenin evades a microRNA-dependent regulatory loop. Proc Natl Acad Sci USA. 2011; 108: 4840-5.
20. Wang W, Zhao LJ, Tan YX, et al. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis. 2012; 33: 1113-20.
21. Bhatia SN, Balis UJ, Yarmush ML, et al. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J. 1999; 13: 1883-900.
22. Fu H, Tie Y, Xu C, et al. Identification of human fetal liver miRNAs by a novel method. FEBS Lett. 2005; 579: 3849-54.
23. Han K, Gennarino VA, Lee Y, et al. Human-specific regulation of MeCP2 levels in fetal brains by microRNA miR-483-5p. Genes Dev. 2013; 27: 485-90.
24. Yao X, Hu JF, Daniels M, et al. A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis. Clin Cancer Res. 2003; 9: 2719-26.
25. Van Rooij E, Sutherland LB, Qi X, et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007; 316: 575-9.
26. Miyaki S, Sato T, Inoue A, et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev. 2010; 24: 1173-85.
27. Dill H, Linder B, Fehr A, et al. Intronic miR-26b controls neuronal differentiation by repressing its host transcript, ctdsp2. Genes Dev. 2012; 26: 25-30.
28. Qiao Y, Ma N, Wang X, et al. MiR-483-5p controls angiogenesis in vitro and targets serum response factor. FEBS Lett. 2011; 585: 3095-100.
29. Rappolee DA, Sturm KS, Behrendtsen O, et al. Insulin-like growth factor II acts through an endogenous growth pathway regulated by imprinting in early mouse embryos. Genes Dev. 1992; 6: 939-52.
30. Keniry A, Oxley D, Monnier P, et al. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol. 2012; 14: 659-65.
31. Venkatraman A, He XC, Thorvaldsen JL, et al. Maternal imprinting at the H19-Igf2 locus maintains adult haematopoietic stem cell quiescence. Nature. 2013; 500: 345-9.
32. Roeb E, Rose-John S, Erren A, et al. Tissue inhibitor of metalloproteinases-2 (TIMP-2) in rat liver cells is increased by lipopolysaccharide and prostaglandin E2. FEBS Lett. 1995; 357: 33-6.
33. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008; 22: 1276-312.
34. Ghosh T, Soni K, Scaria V, et al. MicroRNA-mediated up-regulation of an alternatively polyadenylated variant of the mouse cytoplasmic {beta}-actin gene. Nucleic Acids Res. 2008; 36: 6318-32.
35. Berezikov E. Evolution of microRNA diversity and regulation in animals. Nat Rev Genet. 2011; 12: 846-60.
36. Li J, Zhang Y, Liu Y, et al. Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis. J Biol Chem. 2013; 288: 23586-96.
37. Hergenreider E, Heydt S, Tréguer K, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol. 2012; 14: 249-56.
38. Zhang Y, Liu D, Chen X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 2010; 39: 133-44.
39. Murakami Y, Toyoda H, Tanaka M, et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS ONE. 2011; 6: e160814.
40. Hou J, Lin L, Zhou W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011; 19: 232-43.